GHRP-2
pralmorelin
A peptide that raises growth hormone. Japan uses it to test for a shortage of that hormone. Not approved in the EU or US.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
- Type
- Raises growth hormone
- Stage
- Medicine outside EU and US
- Safety
- Little data
- Risk of fakes
- High
- Checked
- Not yet
Safety. In people it was given mainly once, as a test for a shortage of growth hormone. We found no data on longer use. Sources: study 1.
Risk of fakes. Found in supplements and in seized vials with no label. An altered black-market version, Gly-GHRP-2, has also turned up. Sources: study 1, study 2, study 3.
Is it legal
| Where | Status | Checked | |
|---|---|---|---|
| PL | No approval | The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source | Not yet |
| EU | No approval | The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source | Not yet |
| US | No approval | The FDA drug register has no such medicine. Source | Not yet |
How much research exists
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
What studies show
- DMuscle mass
Not clear. One study with random groups in 33 critically ill men over 5 days: it restored growth hormone release and IGF-1. Muscle was not measured, and the men were not healthy.
Reported side effects
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
Reports to the FDA (USA)
- Reports
- 7
- Of these, serious
- 4
| Most often reported | Reports |
|---|---|
| Pain | 2 |
| Hives | 2 |
| Pain in the upper belly | 1 |
| Hair loss | 1 |
| Anxiety | 1 |
| Joint pain | 1 |
| Raised liver enzyme (AST) | 1 |
| Back pain | 1 |
Serious means the person went to hospital, their life was in danger, they were left with lasting harm, or they died. One report can list several side effects.
Cases described in medical journals
- Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
- Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
Studies we have read
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. | Random groups | Men with prolonged critical illness | 33 | 0.7 wk | – | Unknown |
More papers we found
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
Short answers
- Does GHRP-2 work?
- A peptide that raises growth hormone. Japan uses it to test for a shortage of that hormone. Not approved in the EU or US. Muscle mass: grade D, not clear. One study with random groups in 33 critically ill men over 5 days: it restored growth hormone release and IGF-1. Muscle was not measured, and the men were not healthy.
- Is GHRP-2 legal?
- PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.
- Is GHRP-2 banned in sport?
- Banned in sport, WADA 2026.
- Is GHRP-2 safe?
- Little data. In people it was given mainly once, as a test for a shortage of growth hormone. We found no data on longer use.